A Systematic Review of Research Findings on the Efficacy of Interpersonal Therapy for Depressive Disorders

Department of Psychiatry, Federal University of São Paulo, São Paulo SP 04026-010, Brazil.
European Archives of Psychiatry and Clinical Neuroscience (Impact Factor: 3.53). 05/2005; 255(2):75-82. DOI: 10.1007/s00406-004-0542-x
Source: PubMed


Interpersonal psychotherapy (IPT) is a time-limited psychotherapy for major depression. The aim of this study is to summarize findings from controlled trials of the efficacy of IPT in the treatment of depressive spectrum disorders (DSD) using a meta-analytic approach.
Studies of randomized clinical trials of IPT efficacy were located by searching all available data bases from 1974 to 2002. The searches employed the following MeSH categories: Depression/ Depressive Disorder; Interpersonal therapy; Outcome/Adverse Effects/Efficacy; in the identified studies. The efficacy outcomes were: remission; clinical improvement; the difference in depressive symptoms between the two arms of the trial at endpoint, and no recurrence. Drop out rates were used as an index of treatment acceptability.
Thirteen studies fulfilled inclusion criteria and four meta-analyses were performed. IPT was superior in efficacy to placebo in nine studies (Weight Mean Difference (WMD) - 3.57 [-5.9, -1.16]). The combination of IPT and medication did not show an adjunctive effect compared to medication alone for acute treatment (RR 0.78 [0.30, 2.04]), for maintenance treatment (RR 1.01 [0.81, 1.25]), or for prophylactic treatment (RR 0.70 [0.30, 1.65]). IPT was significantly better than CBT (WMD -2.16 [-4.16,-0.15]).
The efficacy of IPT proved to be superior to placebo, similar to medication and did not increase when combined with medication. Overall, IPT was more efficacious than CBT. Current evidence indicates that IPT is an efficacious psychotherapy for DSD and may be superior to some other manualized psychotherapies.

Download full-text


Available from: Marcelo Feijo Mello
    • "In a large RCT, Elkin et al. (1989) found that IPT is equally effective to medication and CBT, with some evidence for increased efficacy of IPT for severely depressed patients. There is also preliminary evidence suggesting the superiority of IPT over alternative psychotherapies (Cuijpers et al. 2008, 2011), specifically supportive counselling (Barth et al. 2013) and CBT (de Mello et al. 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the past several decades, increasing evidence supports the efficacy of psychotherapies for depression. The vast majority of findings from meta-analyses, randomized clinical trials (RCTs) and naturalistic studies have demonstrated that well-established psychotherapies (behavioural activation, problem-solving therapy, psychodynamic therapy, cognitive-behavioural therapy, interpersonal therapy and emotion-focused therapy) are superior to no-treatment and control conditions, and are in most cases equally effective in treating depression. However, despite this abundant support for psychotherapies, studies have also consistently shown high drop-out rates, high percentages of non-respondent patients who experience treatment failures, and mixed findings regarding the enduring effects of psychotherapy. Thus, there is a need to develop more personalised treatment models tailored to patients' needs. A new integrative sequential stepwise approach to the treatment of depression is suggested.
    No preview · Article · Sep 2015 · Epidemiology and Psychiatric Sciences
  • Source
    • "The Development Group investigated pre-existing domestic and international treatment guidelines, as well as trends in the management of depression among Korean psychiatrists. Subsequently, the Development Group analyzed the results of previous investigations (10-50) and developed a non-pharmacological treatment guideline for depression. The Development Group also assessed the domestic status of depression treatments in Korea. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although pharmacological treatment constitutes the main therapeutic approach for depression, non-pharmacological treatments (self-care or psychotherapeutic approach) are usually regarded as more essential therapeutic approaches in clinical practice. However, there have been few clinical practice guidelines concerning self-care or psychotherapy in the management of depression. This study introduces the 'Evidence-Based, Non-Pharmacological Treatment Guideline for Depression in Korea.' For the first time, a guideline was developed for non-pharmacological treatments for Korean adults with mild-to-moderate depression. The guideline development process consisted of establishing several key questions related to non-pharmacologic treatments of depression, searching the literature for studies which answer these questions, assessing the evidence level of each selected study, drawing up draft recommendation, and peer review. The Scottish Intercollegiate Guidelines Network grading system was used to evaluate the quality of evidence. As a result of this process, the guideline recommends exercise therapy, bibliotherapy, cognitive behavior therapy, short-term psychodynamic supportive psychotherapy, and interpersonal psychotherapy as the non-pharmacological treatments for adult patients with mild-to-moderate depression in Korea. Hence, it is necessary to develop specific methodologies for several non-pharmacological treatment for Korean adults with depression.
    Full-text · Article · Jan 2014 · Journal of Korean Medical Science
  • Source
    • "Moving towards additional treatment options, cognitive behaviour psychotherapy has demonstrated efficacy in mild as well as severe depression, with a lower relapse rate as compared to pharmacotherapy [8]. Interpersonal psychotherapy proved superior efficacy as compared to placebo treatment, displaying similar efficacy and acceptability as pharmacological treatments [9]. Therapeutic options based on physical treatments chiefly include electroconvulsive therapy, repetitive transcranial magnetic stimulation, exercise, and sleep deprivation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Investigations of preclinical biomarkers for major depressive disorder (MDD) encompass the quantification of proteins, peptides, mRNAs, or small molecules in blood or urine of animal models. Most studies aim at characterising the animal model by including the assessment of analytes or hormones affected in depressive patients. The ultimate objective is to validate the model to better understand the neurobiological basis of MDD. Stress hormones or inflammation-related analytes associated with MDD are frequently measured. In contrast, other investigators evaluate peripheral analytes in preclinical models to translate the results in clinical settings afterwards. Large-scale, hypothesis-free studies are performed in MDD models to identify candidate biomarkers. Other studies wish to propose new targets for drug discovery. Animal models endowed with predictive validity are investigated, and the assessment of peripheral analytes, such as stress hormones or immune molecules, is comprised to increase the confidence in the target. Finally, since the mechanism of action of antidepressants is incompletely understood, studies investigating molecular alterations associated with antidepressant treatment may include peripheral analyte levels. In conclusion, preclinical biomarker studies aid the identification of new candidate analytes to be tested in clinical trials. They also increase our understanding of MDD pathophysiology and help to identify new pharmacological targets.
    Full-text · Article · Jul 2013 · Disease markers
Show more